ライフサイエンスコーパス: oestradiol

1 locked by 17beta-oestradiol, but not 17alpha-oestradiol.

2 observed for ER's endogenous hormone, 17beta-oestradiol.

3 P gamma S(in) occluded the effect of 17 beta-oestradiol.

4 on complexes for riboflavin, L-thyroxine and oestradiol.

5 HT), a form of testosterone not converted to oestradiol.

6 HT), a form of testosterone not converted to oestradiol.

7 olume was significantly influenced by 17beta-oestradiol.

8 secretion, responses that were augmented by oestradiol.

9 , but not with chronic progesterone or acute oestradiol.

10 nistration of physiological levels of 17beta-oestradiol (0.08 mg/kg/day) in vivo.

11 Dawley rats were ovariectomised and a 17beta-oestradiol (0.25 mg, 21 day release) or placebo pellet i

12 trations similar to those achieved with oral oestradiol 1-2 mg, with lower intra-patient and inter-pa

13 17beta-Oestradiol (1 microM), reported to potentiate BKCa curre

14 increased (118%) with oestradiol treatment (oestradiol=124+/-84.5, placebo=57+/-46.4 mm3, mean+/-SD,

15 cultured for 2-4 days with or without 0.2 nM oestradiol-17 beta (E2) before use.

16 four of them being natural (oestriol, 17beta-oestradiol, 17alpha-oestradiol and oestrone), four being

17 Treatment with oestradiol-17beta (E2beta), but not progesterone or thei

18 an ER antagonist on exogenous and endogenous oestradiol-17beta (E2beta)-mediated elevations in UBF.

19 Treatment of monolayers with 20 nm oestradiol-17beta produced a 2-fold increase in SK3 mRNA

20 he biologically active metabolites of 17beta-oestradiol, 2-hydroxyoestradiol (2-OHE2 ) and 4-hydroxyo

21 tment (n=34; 3 months of transdermal 17 beta-oestradiol 200 micrograms daily alone, then 3 months wit

22 Administration of oestradiol, a hormone produced mainly in the ovaries, in

23 of gonadotropin-releasing hormone (GnRH) or oestradiol (administered as patches or implants), effect

24 .6 ng (100 ml tissue)-1 min-1) acute 17 beta-oestradiol administration.

25 tective benefits previously seen with 17beta-oestradiol after spinal cord injury may be in part due t

26 Serum oestradiol analyses were performed with radioimmunoassay

27 lpha-hydroxytestosterone to oestrone, 17beta-oestradiol and 17beta,16alpha-oestriol, respectively.

28 ns, and that there is an interaction between oestradiol and BCO in the control of PGHS-2 expression i

29 ance of PGHS-2 protein was increased by both oestradiol and BCO in the hippocampus.

30 anisms of the catecholoestradiols, to 17beta-oestradiol and catecholamines, we observed that converge

31 iation between serum concentrations of total oestradiol and cognitive function, but these measurement

32 tocin precursor gene as biomarker for 17beta oestradiol and dexamethasone treatment in beef cattle, a

33 and 13.3-fold in cattle treated with 17beta oestradiol and dexamethasone, respectively, in compariso

34 en in the high tertile for non-protein-bound oestradiol and in 17 (16%) of 106 in the low tertile (od

35 nNOS correlated directly with plasma 17beta-oestradiol and inversely with the magnitude of sympathet

36 nopausal symptoms is similar to that of oral oestradiol and is also well-tolerated.

37 atural (oestriol, 17beta-oestradiol, 17alpha-oestradiol and oestrone), four being synthetic (17alpha-

38 Plasma 17beta-oestradiol in oestradiol and placebo groups was 72.6+/-38.0 and 9.3+/-

39 Follicular and luteal oestradiol and progesterone serum titres were grouped in

40 We then compared serum oestradiol and progesterone titres during these days of

41 A2 mutations are exposed to higher titres of oestradiol and progesterone-known risk-factors for breas

42 nction is mediated by an interaction between oestradiol and prostaglandin biosynthesis in the fetal b

43 ations of non-protein-bound and bioavailable oestradiol and total and non-protein-bound testosterone

44 valid marker for detection of illicit 17beta oestradiol and/or dexamethasone use in beef cattle.

45 omplex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at

46 teroids digitoxigenin, progesterone and beta-oestradiol, and this steroid binding preference can be r

47 APKs involved in catecholoestradiol-, 17beta-oestradiol- and catecholamine-induced endothelial cell p

48 shown that high concentrations of endogenous oestradiol are associated with an increase in risk.

49 We tested the hypothesis that oestradiol attenuates peripheral cutaneous adrenergic re

50 We conclude that oestradiol augments the activity of the central barorece

51 es the expression of PGHS isoforms, and that oestradiol augments the PGHS response to cerebral hypope

52 ction between peptides and PDIp, with 17beta-oestradiol being the most potent inhibitor.

53 heifers (n = 5), steers (n = 5) treated with oestradiol benzoate (0.15 mg/kg body weight) and untreat

54 I, in ovariectomized (OVX) rats treated with oestradiol benzoate (EB).

55 utaneous injections of PPT (10 mg kg(-)(1)), oestradiol benzoate (EB; 20 mug kg(-)(1)), the ERbeta ag

56 d not differ by tertile of non-protein-bound oestradiol, bioavailable oestradiol, or testosterone.

57 d by ATP and tamoxifen was blocked by 17beta-oestradiol, but not 17alpha-oestradiol.

58 this nonapeptide only in cattle after 17beta oestradiol, but not after dexamethasone or placebo treat

59 ations of non-protein-bound and bioavailable oestradiol, but not testosterone, were less likely to de

60 by chronic treatment of OVX rats with 17beta-oestradiol, but not with chronic progesterone or acute o

61 pendent on the conversion of testosterone to oestradiol by aromatase.

62 Oestradiol, by itself, increased the abundance of PGHS-2

63 la were 13000-22000 times higher than plasma oestradiol concentrations in early life, and may be suff

64 The rise in fetal PGE(2) and maternal oestradiol concentrations post-Dex occurred earlier in t

65 Serum oestradiol concentrations were also significantly reduce

66 to changes in total or free testosterone, or oestradiol concentrations.

67 We also found that the 17beta-oestradiol decreased Ca(2+) retention in brain mitochond

68 ere measured in beef cattle receiving 17beta oestradiol, dexamethasone or placebo over a period of 40

69 We have investigated rapid effects of 17beta-oestradiol (E) on prolactin (PRL) release in vitro.

70 Myocytes were incubated +/-17beta-oestradiol (E2 = 1 nm) and INCX was measured on days 0,

71 Y POINTS: The catechol metabolites of 17beta-oestradiol (E2 beta), 2-hydroxyoestradiol (2-OHE2 ) and

72 tudies have demonstrated protection of serum oestradiol (E2) against oxidative stress through upregul

73 17 beta-Oestradiol (E2) at 0.1-10 microM directly inhibited vari

74 The impact of 17beta-oestradiol (E2) exposure on autonomic control of orthost

75 ort that in human breast cancer cells 17beta-oestradiol (E2)-bound oestrogen receptor alpha (ER-alpha

76 Oestradiol (E2, 0.2 mg day-1, patch; days 4-16), and pro

77 ng pregnant rats a high-fat (HF)- or ethinyl-oestradiol (EE2)-supplemented diet affects carcinogen-in

78 S21400 increased serum oestradiol exposure dose-dependently, to concentrations

79 The results were similar for bioavailable oestradiol (five [5%] vs 15 [15%]; adjusted odds ratio 0

80 s between the S21400 and the placebo or oral oestradiol groups, except for a greater incidence of sne

81 In contrast, oestradiol had no significant effect on the abundance of

82 increases in fetal plasma concentrations of oestradiol have a neuroendocrine effect to increase both

83 ves were repeated in the presence of 17 beta-oestradiol in 20 of the 31 non-users.

84 Higher titres of oestradiol in carriers are compatible with this hormone

85 Plasma 17beta-oestradiol in oestradiol and placebo groups was 72.6+/-3

86 te testis fluids, which is higher than serum oestradiol in the female.

87 he positive and negative feedback effects of oestradiol in the hypothalamic anteroventral periventric

88 uman Msx-2 homologue was regulated by 17beta-oestradiol in the MCF-7 breast cancer cell line.

89 ggest that the non-genomic action of 17 beta-oestradiol in the potentiation of kainate-induced curren

90 p53 (p53 is induced upon binding of p53ER to oestradiol) in a p53-deficient cell line, we found that

91 We found that oestradiol increased Fos abundance in nucleus tractus so

92 ent with a high physiological dose of 17beta-oestradiol increased infarct volume after permanent MCAO

93 ts were designed to test the hypothesis that oestradiol increases the expression of PGHS isoforms, an

94 We conclude that oestradiol increases the expression of PGHS-2 in specifi

95 Progesterone can block the oestradiol-induced GnRH/LH surge and inhibit LH pulse fr

96 rogen action enhancing torsadogenic effects: oestradiol interaction with hERG mutations in the pore l

97 which, on binding the steroid hormone 17beta-oestradiol, interacts with co-activator proteins and sti

98 Intranasally administered 17beta-oestradiol is significantly better than placebo; its eff

99 or the inverse relationship between FVII and oestradiol levels observed during the menstrual cycle.

100 administration, and serum gonadotropins and oestradiol measured.

101 ogical deficits were similar between groups (oestradiol median=13, placebo=14, max score=33).

102 clude that the conversion of testosterone to oestradiol modulates phrenic and XII LTF in male F344 ra

103 n concert with an internal action of 17 beta-oestradiol on a cAMP-dependent phosphorylation.

104 culate that at least a part of the effect of oestradiol on fetal HPA axis function is mediated by an

105 of allopregnanolone, progesterone and 17beta-oestradiol on oxytocin and vasopressin release from inta

106 nt study was performed to test the effect of oestradiol on the central baroreceptor and chemoreceptor

107 f non-protein-bound oestradiol, bioavailable oestradiol, or testosterone.

108 Furthermore, 17beta-oestradiol protected G93A cortical neurons and spinal co

109 l CA1 neurones, we demonstrated that 17 beta-oestradiol rapidly potentiates kainate-induced currents

110 s implantation of a pellet containing 17beta-oestradiol (release rate 5 mg (21 days)-1).

111 were either ovariectomized and given 17beta-oestradiol replacement (OVXE2) or sham ovariectomized wi

112 In addition, while 17beta-oestradiol replacement at the end of the long-term oestr

113 After 1 month of transdermal oestradiol replacement in these women, the normal effect

114 provide increased support that early 17beta-oestradiol replacement is critical in preventing the neg

115 otent suppressor of follicle development and oestradiol secretion in women.

116 Intra-arterial infusion of 17 beta-oestradiol significantly potentiated bradykinin-induced

117 An intranasal 17beta-oestradiol spray, S21400, which bypasses such drawbacks,

118 In separate experiments, we have found that oestradiol stimulates fetal HPA axis activity.

119 xyoestradiol (2-ME), a natural metabolite of oestradiol that is elevated during the third trimester o

120 ro culture system we demonstrate that 17beta-oestradiol treatment (50 nM) is sufficient to increase g

121 lume was significantly increased (118%) with oestradiol treatment (oestradiol=124+/-84.5, placebo=57+

122 d (2) that the conversion of testosterone to oestradiol (under the influence of aromatase) is require

123 0 microg, 300 microg, or 400 microg, or oral oestradiol valerate in doses of 1 mg or 2 mg, daily for

124 tion of hot flashes and, for the first time, oestradiol was detected in the serum.

125 ersensitivity and amyloidogenesis, if 17beta-oestradiol was initiated at the time of ovariectomy and

126 24% of male multiple sclerosis patients and oestradiol was low in 25% of pre-menopausal female multi

127 At the 24 h end point, plasma oestradiol was measured and brain sections stained with

128 ation of kainate-induced currents by 17 beta-oestradiol was occluded by cholera toxin pretreatment an

129 in women negative for the mutations, and for oestradiol were 33% higher (p=0.007)-ie, 59% of carriers

130 However, unlike 17beta-oestradiol, which induces proliferation via oestrogen re